What's new?

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development

December 03, 2020 03:00 AM Eastern Standard Time   MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announc...

Redx Pharma plc Placing to raise c.£25.5 million and Open Offer to raise up to £2.2 million and Conversion of loan notes

Alderley Park, 2 December 2020 - Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces today that it has conditionally raised c.£25.5 million (before expenses) by way of a placing of 45,603,575 new Ordinary Shares (the "Placing Shares") with both new institutional in...

Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners

In-licensing of four clinical-stage product candidates to treat orphan neurological disorders Highly experienced team leverages latest scientific discoveries in neuroscience Financing will advance the development of four clinical-stage product candidates Strong participation from international syndicate of investor...

Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf CAR-NK Cell Therapies to Treat Solid Tumors

Company brings together scientific founders with leading-edge expertise in NK cells and leadership team with deep cell therapy experience   Proceeds to advance two lead CAR-NK cell therapy programs based on the company’s TAILWIND™ Platform   November 23, 2020 07:00 AM Eastern Standard Time   CAMBRIDGE, Mass.--(BUSI...

Pixium Vision receives French regulatory authority (ANSM) approval to initiate European PRIMAvera pivotal study of Prima System

Paris, November 20, 2020 – 07.00 CET– Pixium Vision (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, today announces it has received approval from the French regulatory health auth...

Michelin and Pyrowave Join Forces to Industrialize an Innovative Plastic Waste Recycling Technology

- Michelin Group and the Canadian firm Pyrowave join forces to accelerate time-to-market for an innovative plastic waste recycling technology. - They agree to fast track the process industrialization. - The purpose of the technology is to increase the rate of sustainable materials not only in Michelin tires, but al...

TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant

IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant   TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption...

Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer

● Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer ● Initial financing of £4.5M from venture capital syndicate of experienced life sciences investo...

Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Nov 8, 2020 - Calliditas Therapeutics AB (OMX Nasdaq: CALTX, NASDAQ: CALT) (”Calliditas”) today announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy (IgAN).

GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

Paris, France, Tuesday, November 3, 2020, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported that...

1 2 3 ... 182